



Patent  
Our Docket: 5062CIP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Wadsworth et al. )  
Application No.: 10/716,326 )  
Filing Date: November 17, 2003 )  
For: Methods of Treating Diabetes and )  
and Other Blood Sugar Disorders )

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE IN AN ENVELOPE ADDRESSED TO: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450**

March 30, 2004  
Date

Talyn Antalek  
Signature of person mailing correspondence

**Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures**

This Communication is being filed in response to the Notice to Comply with Requirements for Patent Applications containing Sequence and/or Amino Acid Sequence Disclosures mailed 30 January 2004 in connection with the above referenced patent application. A response to this Notice to Comply is due on 30 March 2004. Accordingly, this response is timely filed.

In response to this Invitation, Applicants hereby submit a nucleotide and amino acid sequence listing in computer readable form (compact disk) that complies with 37 CFR 1.821(e), 1.821(f), 1.821(g) and 1.821(h). Applicants hereby also submit the statement required by this Invitation that the sequence listing information recorded in

computer readable form is identical to the written sequence listing. As such, the sequence listing information recorded in computer readable form contains no new matter.

Respectfully submitted,

3/30/04  
Date

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, MA 01701-9322

Jennifer D. Tousignant  
Jennifer D. Tousignant

Agent for Applicant  
Registration No. 54,498  
Telephone: (508) 270-2499  
Facsimile: (508) 872-5415